Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.
Saved in:
| Title: | Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma. |
|---|---|
| Authors: | Wobser M; Department of Dermatology, University Hospital Wuerzburg, Germany.; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany., Rosenwald A; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Institute of Pathology, University Wuerzburg, Germany., Eisele F; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Department of Internal Medicine, Hematology/Oncology, University Hospital Wuerzburg, Germany., Maurus K; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Institute of Pathology, University Wuerzburg, Germany., Topp M; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Department of Internal Medicine, Hematology/Oncology, University Hospital Wuerzburg, Germany., Duell J; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Department of Internal Medicine, Hematology/Oncology, University Hospital Wuerzburg, Germany. |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2026 Aug; Vol. 67 (9), pp. 1990-1993. Date of Electronic Publication: 2026 May 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
